|
a phase iib/iii, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis
|
28-07-202227-12-2025
|
Penyelidik Bersama
|
|
assessing the efficacy of a multi-strain probiotics in combination with standard care in mild to moderate ulcerative colitis
|
01-10-202330-09-2025
|
Penyelidik Bersama
|
|
a phase 2b/3, randomized, double-blind, placebo-controlled, parallel-group, multicenter protocol to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis
|
18-02-202117-07-2025
|
Ketua Projek
|
|
-
|
01-08-202331-12-2024
|
Ahli Kumpulan
|
|
prevalence of liver fibrosis based on fib-4 score and transient elastography in hiv mono-infected patients and its associated risk factors
|
22-02-202421-11-2024
|
Penyelidik Bersama
|
|
a phase 3, multicenter, open-label extension study to evaluate the long term efficacyand safety of mirikizumab in patients with moderately to severely active ulcerativecolitis(protocol no.: i6t-mc-amap)
|
13-10-201912-10-2024
|
Penyelidik Bersama
|
|
exploring diet, physical activities and host’s interaction with colonic mucosal microbiota population in young colorectal cancer
|
24-09-202023-09-2024
|
Penyelidik Bersama
|
|
m16-067: a multicenter, randomized, double-blind, placebo-controlled induction study to evaluate the efficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis who have failed prior biologic therapy
|
12-09-201911-09-2024
|
Penyelidik Bersama
|
|
m16-066:a multicenter,randomized,double-blind,placebo-controlled 52-week maintenance and an open label extension study of the efficacy and safety of risankizumab in subjects with ulcerative colitis who responded to induction treatment in m16-067 0r 065
|
12-09-201911-09-2024
|
Penyelidik Bersama
|
|
combining microbial, integrin expression and dietary pattern in crohn’s disease patients treated with anti-integrin
|
01-09-202131-08-2024
|
Penyelidik Bersama
|
|
-
|
28-07-202227-07-2024
|
Ketua Projek
|
|
combined phase 3, double-blind, randomized, placebo-controlled studies evaluating the efficacy and safety of filgotinib in the induction and maintenance of remission in subjects with moderately to severely active crohn`s disease
|
16-03-201715-07-2024
|
Penyelidik Bersama
|
|
tocotrienol as a treatment for non-alcoholic fatty liver disease: a randomized controlled trial
|
10-04-202030-06-2024
|
Penyelidik Bersama
|
|
m14-675: a multicenter, randomized, double-blind, placebo-controlled induction study to evaluate the efficacy and safety of upadacitinib (abt-494) in subjects with moderately to severely active ulcerative colitis
|
13-06-201912-06-2024
|
Penyelidik Bersama
|
|
the clinical utility of biomarkers afp-l3 and pivka ii as a tool for hepatocellular carcinoma screening in ukmmc
|
24-02-202223-05-2024
|
Penyelidik Bersama
|
|
prevalence of metabolic dysfunction-associated fatty liver (mafld) among nurses in a single tertiary care centre and the role of intermittent fasting in improving hepatic steatosis.
|
02-05-202301-05-2024
|
Ketua Projek
|
|
regulation of mucin, claudin and zonulin in maintaining intestinal barrier function in inflammatory bowel disease
|
01-11-202030-04-2024
|
Penyelidik Bersama
|
|
interactions between the gut microbiota and host intestinal barrier genes in young-onset colorectal cancer
|
01-08-202030-04-2024
|
Penyelidik Bersama
|
|
tocotrienol as a treatment for non-alcoholic fatty liver disease: a randomized controlled trial
|
10-04-202009-04-2024
|
Penyelidik Bersama
|
|
elucidating the roles of long noncoding rnas (lncrnas) from lipotoxic hepatocyte-extracellular vesicles (hepatocyte-evs) in the liver fibrosis formation
|
01-09-202129-02-2024
|
Penyelidik Bersama
|
|
exploring the roles of mirnas on lipidome of metabolic-associated fatty liver disease (mafld) cell models
|
10-01-202309-01-2024
|
Penyelidik Bersama
|
|
tajuk program: linking obesity to cancer: an integrative study from molecule to society
tajuk projek: identification of risk factors associated with colon cancer prognosis, disease free survival and recurrence in obese individuals
|
01-02-201931-12-2023
|
Penyelidik Bersama
|
|
a phase 3, multicenter, randomized, double-blind, parallel, placebo-controlled induction study of mirikizumab in conventional-failed and biologic-failed patients with moderately to severely active ulcerative colitis(protocol no: 16t-mc-aman)
|
27-12-201826-10-2023
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled induction study of the efficacy and safety of risankizumab in subjects with moderately to severely active crohn`s disease
|
14-09-201713-07-2023
|
Penyelidik Bersama
|
|
a randomized open label pilot study of probiotics as adjunctive therapy for treatment of sle
|
24-01-202123-04-2023
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo controlled maintenance and long term extension study of the efficacy and safety of upadacitinib (abt-494) in subjects with crohn’s disease who completed the m14-431 or m14-433 studies
|
12-04-201811-04-2023
|
Penyelidik Bersama
|
|
a phase 3, multicenter, randomized, double-blind, parallel-arm, placebo-controlled maintenance study of mirikizumab in patients with moderately to severely active ulcerative colitis.protocol no: 16t-mc-ambg
|
27-12-201826-02-2023
|
Penyelidik Bersama
|
|
a phase 3 multicenter, open-label extension (ole) study to evaluate the long-term safety and efficacy of abt-494 in subjects with ulcerative colitis (uc)
|
16-02-201715-02-2023
|
Penyelidik Bersama
|
|
targeting gut-microbiome-brain axis: probiotic have antidepression-like effects and reverse the
impact of chronic stress in rats
|
15-02-201931-12-2022
|
Penyelidik Bersama
|
|
targeting gut-microbiome-brain axis: probiotic have antidepression-like effects and reverse the impact of chronic stress in rats
|
15-02-201931-12-2022
|
Penyelidik Bersama
|
|
a long-term extension study to evaluate the safety of filgotinib in subjects with ulcerative colitis
|
13-04-201712-12-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled 52-week maintenance and an open-label extension study of the efficacy and safety of risankizumab in subjects with crohn`s disease who responded to induction treatment in m16-006 or m15-991
|
26-10-201725-11-2022
|
Penyelidik Bersama
|
|
-
|
21-10-202020-10-2022
|
Ketua Projek
|
|
a multicenter, randomized, double-blind, placebo-controlled induction study to assess the efficacy and safety of risankizumab in subjects with moderately to severely active crohn`s disease who failed prior biologic treatment
|
14-09-201713-10-2022
|
Penyelidik Bersama
|
|
unravelling driver mutations of phosphatidylinositol 3-kinase pathway genes leading to the development of colitis associated cancer
|
01-01-201930-09-2022
|
Penyelidik Bersama
|
|
the association between dietary inflammation potential with the risk of colorectal cancer
|
28-12-201927-04-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled induction study of the efficacy and safety of upadacitinib (abt-494) in subjects with moderately to severely active crohn’s disease who have inadequately responded to or are intolerant to
|
12-04-201811-04-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled induction study of the efficacy and safety of upadacitinib (abt-494) in subjects with moderately to severely active crohn`s disease who have inadequately responded to or are intolerant to biologi
|
12-04-201811-04-2022
|
Penyelidik Bersama
|
|
revealing fecal short chain fatty acids as gut microbiota-derived biomarker in non-alcoholic fatty liver disease
|
01-10-201931-03-2022
|
Ketua Projek
|
|
elucidating probiotics as gut microenvironment modulator in non-alcoholic fatty liver disease
|
01-01-201931-03-2022
|
Ketua Projek
|
|
health-related quality of life of inflammatory bowel disease patients in malaysia
|
26-03-202025-03-2022
|
Penyelidik Bersama
|
|
the effectiveness of intestinal ultrasound in the assessment of inflammatory bowel disease: a prospective study at a tertiary ibd centre
|
13-09-201911-03-2022
|
Ketua Projek
|
|
prevalence of liver injury in covid-19
|
18-02-202117-02-2022
|
Penyelidik Bersama
|
|
a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of abt-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis
|
16-02-201715-02-2022
|
Penyelidik Bersama
|
|
combined phase 2b/3, double-blind, randomized, placebo-controlled studies evaluating the efficacy and safety of filgotinib in the induction and maintenance of remission in subjects with moderately to severely active ulcerative colitis
|
13-04-201712-02-2022
|
Penyelidik Bersama
|
|
phase iii, randomized, double-blind, double-dummy, placebo-controlled, multicenter study to evaluate the efficacy (induction of remission) and safety of etrolizumab compared with adalimuman and placebo in patients with moderate to severe ulcerative coliti
|
26-02-201525-12-2021
|
Penyelidik Bersama
|
|
the effect of probiotic as an adjunct treatment for helicobacter pylori infection in adult
|
24-12-202023-12-2021
|
Penyelidik Bersama
|
|
real-world practice on the efficacy and safety of antiviral therapy in the management of symptomatic covid-19 infection
|
11-06-202010-06-2021
|
Penyelidik Bersama
|
|
interventional strategy in tackling emerging non-alcoholic fatty liver disease in childhood obesity
|
15-08-201814-02-2021
|
Penyelidik Bersama
|